- Details
- Description
Packaging Size:
30 tablets per box
Strength:
0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg
Composition:
Orforglipron
Treatment:
Weight management in adults with obesity or overweight with at least one weight-related comorbidity
Form:
Tablets
Brand:
LuciOrfor
Quantity Unit:
Tablets
Manufacturer:
Lucius Pharmaceuticals (Lao) Co., Ltd.
LuciOrfor (Orforglipron) is an investigational oral medicine that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. It is designed to activate GLP-1 receptors, which can influence blood glucose regulation, appetite, and body weight.
Orforglipron has been studied in clinical trials for the treatment of type 2 diabetes and obesity/overweight. As an oral, non-peptide GLP-1 receptor agonist, it is being developed as a potential alternative to injectable GLP-1 therapies.
The medicine should be used only according to applicable regulatory approval and under the supervision of a qualified healthcare professional.
